Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
Abstract Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles. Medical imaging is the cornerstone for response...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2464 |
id |
doaj-9b4d1df525ef4d32b9e0898b2663f615 |
---|---|
record_format |
Article |
spelling |
doaj-9b4d1df525ef4d32b9e0898b2663f6152020-11-25T01:30:09ZengWileyCancer Medicine2045-76342019-09-018125399541310.1002/cam4.2464Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis predictionHong Wei0Hanyu Jiang1Bin Song2Department of Radiology Sichuan University West China Hospital Chengdu Sichuan Province ChinaDepartment of Radiology Sichuan University West China Hospital Chengdu Sichuan Province ChinaDepartment of Radiology Sichuan University West China Hospital Chengdu Sichuan Province ChinaAbstract Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles. Medical imaging is the cornerstone for response assessment to immunotherapy and plays a critical role in monitoring of immune‐related adverse events (irAEs). Imaging‐based biomarkers have shown tremendous potential for the prediction of therapeutic efficacies and clinical outcomes in patients treated with checkpoint inhibitors. In this article, the landscape of current response assessment systems for immunotherapy was reviewed with a special focus on the latest advances in the assessment of responses to ICB. Emerging imaging biomarkers were discussed along with the challenges regarding their clinical transformation. In addition, the biological mechanisms and clinical applications of ICB and irAEs were also within the scope of this review.https://doi.org/10.1002/cam4.2464biomarkercancerimagingimmune checkpoint blockaderesponse assessment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hong Wei Hanyu Jiang Bin Song |
spellingShingle |
Hong Wei Hanyu Jiang Bin Song Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction Cancer Medicine biomarker cancer imaging immune checkpoint blockade response assessment |
author_facet |
Hong Wei Hanyu Jiang Bin Song |
author_sort |
Hong Wei |
title |
Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction |
title_short |
Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction |
title_full |
Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction |
title_fullStr |
Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction |
title_full_unstemmed |
Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction |
title_sort |
role of medical imaging for immune checkpoint blockade therapy: from response assessment to prognosis prediction |
publisher |
Wiley |
series |
Cancer Medicine |
issn |
2045-7634 |
publishDate |
2019-09-01 |
description |
Abstract Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles. Medical imaging is the cornerstone for response assessment to immunotherapy and plays a critical role in monitoring of immune‐related adverse events (irAEs). Imaging‐based biomarkers have shown tremendous potential for the prediction of therapeutic efficacies and clinical outcomes in patients treated with checkpoint inhibitors. In this article, the landscape of current response assessment systems for immunotherapy was reviewed with a special focus on the latest advances in the assessment of responses to ICB. Emerging imaging biomarkers were discussed along with the challenges regarding their clinical transformation. In addition, the biological mechanisms and clinical applications of ICB and irAEs were also within the scope of this review. |
topic |
biomarker cancer imaging immune checkpoint blockade response assessment |
url |
https://doi.org/10.1002/cam4.2464 |
work_keys_str_mv |
AT hongwei roleofmedicalimagingforimmunecheckpointblockadetherapyfromresponseassessmenttoprognosisprediction AT hanyujiang roleofmedicalimagingforimmunecheckpointblockadetherapyfromresponseassessmenttoprognosisprediction AT binsong roleofmedicalimagingforimmunecheckpointblockadetherapyfromresponseassessmenttoprognosisprediction |
_version_ |
1725093279693799424 |